DHR

Danaher is rated a Buy, with revenue growth expected to accelerate in 2027 as respiratory headwinds fade and bioprocessing shipments recover. DHR's valuation is reasonable, trading at a 12% discount to its five-year average P/E, supported by strong recurring revenues and operational excellence. Life Sciences segment shows robust recovery, with 5.5% core growth and margin expansion, driven by improved pharma spending and biotech funding.

Rainer Blair to retire WASHINGTON, Aug. 3, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") announced that the Company's Board of Directors has appointed Julie Sawyer Montgomery as President and Chief Executive Officer and a member of the Board of Directors, effective October 1, 2026. On that date, Rainer Blair will retire and serve as a senior advisor until March 31, 2027 to ensure a seamless transition.

For the second quarter of 2026, Aristotle Capital's Global Equity WM Composite posted a total return of 6.92% pure gross of fees (6.40% net of fees), underperforming the MSCI ACWI Index, which returned 14.93%, and the MSCI World Index, which returned 13.76%. During the quarter, we sold our positions in Danaher, Dolby Laboratories, and Tokyo Century and purchased Techtronic Industries and Wal-Mart de Mexico. Munich Re, the world's largest reinsurance company, was a detractor during the quarter.

The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Danaher (DHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

There's reason to believe the stock can stage a comeback after its worst day in two decades.

DHR beats Q2 estimates as Life Sciences posts its strongest quarter in years, prompting the company to raise its 2026 adjusted EPS outlook.

Danaher Corporation delivered Q2 revenue of $6.3B (+5.5% y/y), beating estimates and showing segment growth across Biotechnology, Diagnostics, and Life Sciences. Gross margins declined due to higher cost of sales, but operating margins improved significantly on tight SG&A control and DBS-driven productivity. Management raised full-year EPS guidance slightly, but projected low single-digit revenue growth and a slow recovery, disappointing investors and triggering a 14% share price drop.

Danaher Corporation (DHR) Q2 2026 Earnings Call Transcript

The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Danaher NYSE: DHR reported better-than-expected second-quarter 2026 results, with management citing accelerating core revenue growth, stronger life sciences demand and benefits from productivity initiatives, while also addressing investor concerns over delayed bioprocessing shipments.